We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Novel Blood Test Could Reveal Alzheimer’s Disease Biology and Risk for Progression

By LabMedica International staff writers
Posted on 20 Sep 2024
Print article
Image: New Alzheimer’s studies have revealed disease biology, risk for progression, and potential for a novel blood test (Photo courtesy of Adobe Stock)
Image: New Alzheimer’s studies have revealed disease biology, risk for progression, and potential for a novel blood test (Photo courtesy of Adobe Stock)

The inability to diagnose Alzheimer’s disease, the most prevalent form of dementia in the elderly, at an early stage of molecular pathology is considered a key reason why treatments fail in clinical trials. Previous efforts to diagnose Alzheimer’s molecularly have focused on the central biomarkers of β-amyloid, Tau, and Neurodegeneration (A/T/N), which are measured through the analysis of proteins associated with neurodegeneration. A/T/N can be assessed in brain tissue, through in vivo brain imaging techniques, and by analyzing cerebrospinal fluid and plasma. Alzheimer’s disease is believed to be triggered by a combination of genetic and environmental risk factors. Blood-based biomarkers, such as plasma microRNAs (miRNAs)—molecules that regulate interactions between the genome and the environment and control the expression of genes governing brain functions that deteriorate in Alzheimer’s—could offer advantages in terms of cost-effectiveness, accessibility, and reduced invasiveness.

Two new papers by a research team, including investigators from Boston University (Boston, MA, USA), have demonstrated that evaluating microRNAs in blood can be used not only to diagnose mild cognitive impairment (MCI) but also, crucially, to predict the progression from MCI to dementia due to Alzheimer’s disease. Additionally, the researchers identified microRNA candidate molecular biomarkers associated with the current A/T/N Alzheimer’s biomarkers. In their study, the team analyzed miRNA expression in plasma samples from three groups of participants—those who were cognitively normal, those with mild cognitive impairment, and those with dementia due to Alzheimer’s disease. They discovered that, when combined with neuropsychological testing, plasma microRNAome evaluation could help predict which aging individuals concerned about cognitive decline are likely to develop Alzheimer’s.

Although novel therapies for Alzheimer’s disease are beginning to enter clinical care, the researchers emphasize that these treatments will only be effective if patients at risk are identified as early as possible. The researchers highlight the need for improved tools for early detection of Alzheimer’s, which are essential for developing prevention and treatment strategies for a disease that causes significant suffering and places a heavy burden on healthcare systems worldwide. These findings are published in Alzheimer’s & Dementia.

“Our papers are the result of a successful collaboration that tied the technology developed by professor Andre Fischer in Germany’s DZNE to reliably measure the levels of microRNA in human plasma, and the power of blood samples obtained from hundreds of ADNI participants participating in a simulated clinical trial taking place at about 60 medical centers across the US and Canada,” explained one of four senior authors Ivana Delalle, MD, PhD, professor of pathology & laboratory medicine at Boston University Chobanian & Avedisian School of Medicine. “Our discovery is important because, unlike the current A/T/N biomarkers, microRNAs may serve as blood molecular biomarkers years before Alzheimer’s disease manifests clinically, thus identifying the time window for effective prevention or early intervention to stop the progression of Alzheimer’s.”

Gold Member
Pharmacogenetics Panel
VeriDose Core Panel v2.0
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Nutating Mixer
Enduro MiniMix
New
Epstein-Barr Virus Test
Mononucleosis Rapid Test

Print article

Channels

Clinical Chemistry

view channel
Image: The tiny clay-based materials can be customized for a range of medical applications (Photo courtesy of Angira Roy and Sam O’Keefe)

‘Brilliantly Luminous’ Nanoscale Chemical Tool to Improve Disease Detection

Thousands of commercially available glowing molecules known as fluorophores are commonly used in medical imaging, disease detection, biomarker tagging, and chemical analysis. They are also integral in... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Delivers Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Pathology

view channel
Image: The ready-to-use DUB enzyme assay kits accelerate routine DUB activity assays without compromising data quality (Photo courtesy of Adobe Stock)

Sensitive and Specific DUB Enzyme Assay Kits Require Minimal Setup Without Substrate Preparation

Ubiquitination and deubiquitination are two important physiological processes in the ubiquitin-proteasome system, responsible for protein degradation in cells. Deubiquitinating (DUB) enzymes contain around... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.